Early treatment with lorlatinib improves survival in some lung cancer patients

A new study finds that an FDA-approved medication improved survival and prevented metastasis when used as first-line therapy in lung cancer patients with alterations in the ALK gene. Lorlatinib dramatically reduced spread of cancer to the brain, a significant danger in ALK-positive patients. Source

Leave a Reply

Your email address will not be published.